Apoptotic Mechanisms in Cancer Therapeutics

Apoptosis, or programmed cell death, is a finely tuned process that maintains tissue integrity by eliminating damaged or unwanted cells. In cancer, defects in apoptotic pathways enable malignant cells to survive, proliferate and resist treatment. Therapeutic strategies now focus on reinstating controlled cell death by modulating key molecular regulators. The intrinsic pathway is centred on mitochondrial outer membrane permeabilisation, governed by the BCL-2 family’s balance of pro- and anti-apoptotic members. The extrinsic pathway involves activation of death receptors at the cell surface, triggering a cascade of caspases that dismantle the cell. Modern interventions range from small-molecule inhibitors of anti-apoptotic proteins to engineered mimics of BH3-only proteins, each designed to tip the balance towards cell elimination. Advances in structural biology and interaction profiling have refined our understanding of these networks, enabling precision approaches that predict and enhance therapeutic efficacy across diverse malignancies.

Research from Nature Portfolio

Recent studies have elucidated structural and functional determinants of key apoptosis regulators. High-resolution crystal structures of p53 bound to BCL-2 reveal how the tumour suppressor directly competes with pro-apoptotic proteins for the BH3-binding groove, offering a blueprint for molecules that restore cell death in p53-deficient cancers. Concurrently, the development of BRD-810, a selective MCL1 inhibitor with rapid systemic clearance, has demonstrated robust induction of apoptosis in both solid and haematological tumour models while minimising cardiotoxicity. Complementing these findings, single-molecule profiling of BCL-2 family protein–protein interactions in acute myeloid leukaemia has enabled predictive modelling of patient response to BH3-mimetics, identifying specific anti-apoptotic complexes as biomarkers to guide individualised treatment decisions.

Apoptotic Mechanisms in Cancer Therapeutics publication trend

The graph below shows the total number of articles in apoptotic mechanisms in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Apoptosis: Programmed cell death characterised by membrane blebbing, chromatin condensation and DNA fragmentation.

BCL-2 family: Proteins that regulate mitochondrial apoptosis by balancing pro-apoptotic (e.g. BAX, BAK) and anti-apoptotic (e.g. BCL-2, MCL1) members.

BH3 mimetic: Small molecule that mimics the BH3 domain of pro-apoptotic proteins, binding to anti-apoptotic BCL-2 family members and triggering mitochondrial permeabilisation.

MOMP: Mitochondrial outer membrane permeabilisation, the irreversible event in intrinsic apoptosis leading to cytochrome c release and caspase activation.

Caspases: Cysteine proteases that execute apoptosis by cleaving specific substrates; initiator caspases activate effector caspases to dismantle cellular components.

Protein–protein interaction profiling: Quantitative analysis of binding events between apoptosis regulators to predict therapeutic response and tailor treatments.

References

1. Profiling protein–protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia. Nature Biomedical Engineering (2024).
2. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature Cancer (2024).
3. Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity. Nature Communications (2023).
4. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (2016).
5. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics. Advanced Pharmaceutical Bulletin (2019).